Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Michael Hesney"'
Autor:
Robert Adamczyk, Heather Myler, Michael Hesney, Michele Stonier, Elizabeth Colston, Richard Bertz, Matthew Hruska
Publikováno v:
British Journal of Clinical Pharmacology. 80:515-524
Aims This open label study was conducted to assess the effect of renal impairment (RI) on the pharmacokinetics (PK) of peginterferon lambda-1a (Lambda). Methods Subjects (age 18–75 years, BMI 18–35 kg m–2) were enrolled into one of five renal f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e37cb25f967d8c2c1f386e8b4625b027
https://doi.org/10.1111/bcp.12634
https://doi.org/10.1111/bcp.12634
Autor:
Matthew W, Hruska, Robert, Adamczyk, Elizabeth, Colston, Michael, Hesney, Michele, Stonier, Heather, Myler, Richard, Bertz
Publikováno v:
British journal of clinical pharmacology. 80(3)
This open label study was conducted to assess the effect of renal impairment (RI) on the pharmacokinetics (PK) of peginterferon lambda-1a (Lambda).Subjects (age 18-75 years, BMI 18-35 kg m(-2) ) were enrolled into one of five renal function groups: n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f9c9f749c6dc4f81287a2efc12360c14
https://pubmed.ncbi.nlm.nih.gov/25807956
https://pubmed.ncbi.nlm.nih.gov/25807956
Autor:
Kevin J. Petty, Christopher R. Lines, Anup K. Majumdar, Deborah Panebianco, Keith Gottesdiener, Michael R. Goldberg, James Dru, Gail Murphy, Michael Hesney, Jacqueline B. McCrea, Robert A. Blum, M.L Constanzer
Publikováno v:
Clinical Pharmacology & Therapeutics. 74:150-156
Background Aprepitant is a neurokinin1 receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine3 (5-HT3) antagonist. Because aprepitant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0518dffd1b3bd42ea9e66431ab57e5bb
https://doi.org/10.1016/s0009-9236(03)00123-1
https://doi.org/10.1016/s0009-9236(03)00123-1
Autor:
D. Ronald Goldwater, Michael R. Goldberg, Kevin J. Petty, Michael Hesney, Christopher Lines, Marian Iwamoto, Anup K. Majumdar, Paul J. Deutsch, Deborah Panebianco, Cynthia Gargano, M. Gail Murphy, Jacqueline B. McCrea, Robert A. Blum, Keith Gottesdiener
Publikováno v:
Clinical Pharmacology & Therapeutics. 74:17-24
Background Aprepitant is a neurokinin1 receptor antagonist that, in combination with a corticosteroid and a 5-hydroxytryptamine3 receptor antagonist, has been shown to be very effective in the prevention of chemotherapy-induced nausea and vomiting. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07bf8ef092d698298aec0d5f70b98ebf
https://doi.org/10.1016/s0009-9236(03)00066-3
https://doi.org/10.1016/s0009-9236(03)00066-3
Autor:
Michael Hesney, Walter K. Kraft, John Busillo, Kevin M. Gottesdiener, Christian D. Lates, Robert A. Blum, Howard E. Greenberg, Kevin J. Petty, M. Gail Murphy, Scott A. Waldman, Anup K. Majumdar, Sandi Van Buren, Michael R. Goldberg, Laura H. Orlowski, Carolyn M. Hustad, Jacqueline B. McCrea, Deborah Panebianco
Publikováno v:
Clinical Therapeutics. 25:1407-1419
Background: The neurokinin-1-receptor antagonist aprepitant, when given in combination with a corticosteroid and a 5-hydroxytryptamine type 3 (5-HT 3 )-receptor antagonist, has been shown to be effective for the prevention of acute and delated chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa947d2b436ccb38857b9ee4c0ad30e
https://doi.org/10.1016/s0149-2918(03)80128-5
https://doi.org/10.1016/s0149-2918(03)80128-5
Autor:
Deutsch Paul J, R. Haesen, Liwen Xi, G. Mistry, Michael Hesney, Jacqueline B. McCrea, Chester J. Kitchen, S. Holland, Scott A. Waldman, R. L. Lins, Howard E. Greenberg, J.D. Rogers, Kimberly L. Birk, A. K. Majumdar, S. X. Li, Robert A. Blum, Donald G. Musson
Publikováno v:
Antimicrobial Agents and Chemotherapy. 46:3506-3511
Ertapenem (INVANZ) is a new once-a-day parenteral β-lactam antimicrobial shown to be effective as a single agent for treatment of various community-acquired and mixed infections. The single- and multiple-dose pharmacokinetics of ertapenem at doses u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b71db0ef03e455fecc65a3117cff5a2
https://doi.org/10.1128/aac.46.11.3506-3511.2002
https://doi.org/10.1128/aac.46.11.3506-3511.2002
Autor:
J. Ellen Payne, Skai W. Schwartz, Louisa L. Kersh, Richard P. Neafus, Lisa J. Suchower, Michael Hesney, Duane B. Snavely, Charles Liss, Thomas E. Bradstreet, Daniel J. Holder, Rayanne Berman, Susan Linna Belliel, Karen E. Hufnagel, Karen L. Walton-Bowen, Margaret Diponzio Copenhaver
Publikováno v:
Drug Information Journal. 26:31-40
The objective of our course is to provide a general understanding of statistical reasoning, an appreciation of the statistician's role in drug development, and to facilitate effective communication between statisticians and clinical researchers. Brie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4e3ebebd109384694da0075c9e0495e
https://doi.org/10.1177/009286159202600104
https://doi.org/10.1177/009286159202600104
Autor:
Frank A. Franklin, Charles L. Shear, Dennis P. Hurley, Harold W. Schnaper, Alexandra Langendorfer, Michael Hesney, Carlos A. Dujovne, Reagan H. Bradford, David T. Nash, James L. Pool, Athanassios N. Chremos
Publikováno v:
The American Journal of Medicine. 91:S18-S24
In the multicenter, double-blind EXCEL (Expanded Clinical Evaluation of Lovastatin) study the efficacy of lovastatin in modifying plasma lipids and lipoproteins in 8,245 participants with moderate primary hypercholesterolemia was evaluated. Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d54a75d9177caf6063e6238ced2b5240
https://doi.org/10.1016/0002-9343(91)90052-y
https://doi.org/10.1016/0002-9343(91)90052-y
Autor:
Frank A. Franklin, Harold W. Schnaper, Alexandra Langendorfer, Dennis P. Hurley, Carlos A. Dujovne, Jim Higgins, Athanassios N. Chremos, James L. Pool, David T. Nash, Maria Downton, A. Lawrence Gould, Michael Hesney, Charles L. Shear, Reagan H. Bradford
Publikováno v:
Archives of Internal Medicine. 151:43-49
In the Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, we evaluated the efficacy and safety of lovastatin in 8245 patients with moderate hypercholesterolemia. Patients were ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b266d0755d3157342a32b5a51a617f3
https://doi.org/10.1001/archinte.151.1.43
https://doi.org/10.1001/archinte.151.1.43
Autor:
James L. Pool, Alexandra Langendorfer, Michael Hesney, Harold W. Schnaper, Charles L. Shear, Carlos A. Dujovne, Wendy P. Stephenson, Jim Higgins, Athanassios N. Chremos, Frank A. Franklin, Reagan H. Bradford
Publikováno v:
The American Journal of Cardiology. 66:B44-B55
The randomized, double-blind, placebo-controlled trial described in this report was undertaken to clarify the dose-response relation of lovastatin therapy to lipid-modifying efficacy (lipid/lipoprotein modification) and drug-related adverse events in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9820ade2c59b463d23f2534362d0d787
https://doi.org/10.1016/0002-9149(90)90440-c
https://doi.org/10.1016/0002-9149(90)90440-c